CE MULTIMEDIA ACTIVITIES January 2012 Despite the fact that gout can be diagnosed with relative certainty and that effective therapies have been available for a long time, gout is underdiagnosed and undertreated, management is less than optimal, and poor clinical outcomes are not uncommon. It is the aim of this CE activity to provide information that will assist primary care providers to improve management and clinical outcomes for their patients with gout. Specifically, the program will convey the key factors needed to confidently make a presumptive diagnosis of gout, explore the rationale, timing and duration of pharmacologic treatment of gout and hyperuricemia, discuss the importance of achieving a target SUA level of ≤6.0 mg/dL with urate lowering therapy (ULT), and provide examples of how to educate and communicate with patients to improve adherence to urate-lowering therapy and overall outcomes. Commercial Support: This activity is supported by an educational grant from Takeda Pharmaceuticals North America, Inc. July 2011 Because nearly 80% of US adults will contract an HPV infection in their lifetime, strategies must be developed to overcome barriers to vaccination and reduce the spread of infection which can lead to cervical, anal, penial, and various head and neck cancers. With approval of the quadrivalent HPV vaccine for prevention of genital warts in males and anal cancer in men and women, it becomes important to broaden the discussion to include strategies to reduce the incidence of HPV infection in males as well. This program is intended to help clinicians recognize barriers to vaccination, understand current clinical evidence, and to effectively communicate/counsel their female and male patients and their parents about the clinical evidence, safety, and efficacy of available vaccines. Commercial Support: This activity is supported by an educational grant from Merck & Co., Inc. |
